Cytogenetic status and oxidative DNA-damage induced by atorvastatin in human peripheral blood lymphocytes: Standard and Fpg-modified comet assay

Toxicology and Applied Pharmacology

Volumn 231, Issue 1, 2008, Pages 85-93

  Gajski, Goran ^a   Garaj Vrhovac, Vera ^a   Oreščanin, Višnja ^b  

^a INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Atorvastatin; Comet assay; Fpg modified comet assay; Micronucleus test; Oxidative DNA damage; Peripheral blood human lymphocytes

Indexed keywords

ATORVASTATIN; REACTIVE OXYGEN METABOLITE;

ADULT; ANALYTIC METHOD; ARTICLE; CELL NUCLEUS; COMET ASSAY; CONTROLLED STUDY; CYTOGENETICS; DNA DAMAGE; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MICRONUCLEUS TEST; OXIDATIVE STRESS; PERIPHERAL LYMPHOCYTE; REGRESSION ANALYSIS;

ADULT; CELL SURVIVAL; COMET ASSAY; CYTOGENETICS; DNA DAMAGE; DNA-FORMAMIDOPYRIMIDINE GLYCOSYLASE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LYMPHOCYTES; MALE; MICRONUCLEUS TESTS; MUTAGENICITY TESTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PYRROLES;

EID: 48549084307     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.03.013     Document Type: Article

References (68)

1. Armitage J. The safety of statins in clinical practice. Lancet 370 9601 (2007) 1781-1790
2. Bender M.A., Preston R.J., Leonard R.C., Pyatt B.E., Gooch P.C., and Shelby M.D. Chromosomal aberration and sister-chromatid exchange frequencies in peripheral blood lymphocytes of a large human population sample. Mutat. Res. 204 3 (1988) 421-433
3. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350 15 (2004) 1495-1504
4. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
5. Ciaravino V., Kropko M.L., Rothwell C.E., Hovey C.A., and Theiss J.C. The genotoxicity profile of atorvastatin, a new drug in the treatment of hypercholesterolemia. Mutat. Res. 343 2-3 (1999) 95-107
6. Collins A.R. Comet assay for DNA damage and repair: principles, applications and limitations. Mol. Biotechnol. 26 (2004) 249-261
7. Collins A.R., Duthie S.J., and Dobson V.L. Direct enzymic detection of endogenous oxidative base damage in human lymphocyte DNA. Carcinogenesis 14 (1993) 1733-1735
8. Collins A.R., Ma A.G., and Duthie S.J. The kinetics of repair of oxidative DNA damage (strand breaks and oxidised pyrimidine) in human cells. Mutat. Res. 336 (1995) 69-77
9. Collins A., Dusinská M., Franklin M., Somorovská M., Petrovská H., Duthie S., Fillion L., Panayiotidis M., Raslová K., and Vaughan N. Comet assay in human biomonitoring studies: reliability, validation, and applications. Environ. Mol. Mutagen. 30 (1997) 139-146
10. Collins A.R., Mitchell D.L., Zunino A., de Wit J., and Busch D. UV-sensitive rodent mutant celllines of complementation groups 6 and 8 differ phenotypically from their human counterparts. Environ. Mol. Mutagen. 29 (1997) 152-160
11. Collins A.R., Dusinská M., and Horská A. Detection of alkylation damage in human lymphocyte DNA with the comet assay. Acta Biochim. Pol. 48 (2001) 611-614
12. Collins A.R., Dusinská M., Horváthová E., Munro E., Savio M., and Stětina R. Inter-individual differences in repair of DNA base oxidation, measured in vitro with the comet assay. Mutagenesis 16 4 (2001) 297-301
13. Comet Assay interest group website. http://cometassay.com/ (accessed 01, 2008).
14. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., and Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84 (1999) 413-428
15. Crick D.C., Andres D.A., Danesi R., Macchia M., and Waechter C.J. Geranyl-geraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells. J. Neurochem. 70 (1998) 2397-2404
16. Crott J.W., Mashiyama S.T., Ames B.N., and Fenech M. The effect of folic acid deficiency and MTHFR C677T polymorphism on chromosome damage in human lymphocytes in vitro. Cancer Epidemiol. Biomarkers Prev. 10 10 (2001) 1089-1096
17. Dale K.M., White C.M., Henyan N.N., Kluger J., and Coleman C.I. Impact of statin dosing intensity on transaminase and creatine kinase. Am. J. Med. 120 8 (2007) 706-712
18. Fenech M. The in vitro micronucleus technique. Mutat. Res. 455 (2000) 81-95
19. Fenech M. Cytokinesis-block micronucleus assay evolves into a "cytome "assay of chromosomal instability, mitotic dysfunction and cell death. Mutat. Res. 600 1-2 (2006) 58-66
20. Fenech M., and Morley A.A. Measurement of micronuclei in lymphocytes. Mutat. Res. 147 (1985) 29-36
21. Fenech M., Chang W.P., Kirsch-Volders M., Holland N., Bonassi S., and Zeiger E. HUMN project: detailed description of scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat. Res. 534 (2003) 65-75
22. Furberg C.D., and Pitt B. Withdrawal of cerivastatin from the world market. Curr. Control Trials, Cardiovasc. Med. 2 (2001) 205-207
23. Gajski G., and Garaj-Vrhovac V. Application of cytogenetic endpoints and comet assay on human lymphocytes treated with atorvastatin in vitro. J. Environ. Sci. Health A Tox. Hazard. Subst. Environ. Eng. 43 1 (2008) 78-85
24. Goldber R.B., Mellies M.J., Sacks F.M., Moye L.A., Howard B.V., Howard W.J., Davis B.R., Cole T.G., Pfeffer M.A., and Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucoseintolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial: the Care Investigators. Circulation 98 (1998) 2513-2519
25. Grundy S.M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia, N. Engl. J. Med. 319 (1988) 24-33
26. Grundy S.M. The issue of statin safety: where do we stand?. Circulation 111 23 (2005) 3106-3109
27. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. ational Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
28. Guerin M., Lassel T.S., Le-Goff W., Farnier M., and Chapman M.J. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 189-197
29. Hamilton-Craig I. Statin-associated myopathy. Med. J. Aust. 175 (2001) 486-489
30. Harangi M., Seres I., Varga Z., Emri G., Szilvássy Z., Paragh G., and Remenyik É. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur. J. Clin. Pharmacol. 60 (2004) 685-691
31. Hartman A., Plappert U., Poetter F., and Suter W. Comparative study with the alkaline comet assay and the chromosome aberration test. Mutat. Res. 536 (2003) 27-38
32. He J.L., Chen W.L., Jin L.F., and Jin H.Y. Comparative evaluation of the in vitro micronucleus test and the comet assay for the detection of genotoxic effects of X-ray radiation. Mutat. Res. 469 2 (2000) 223-231
33. Henderson L., Wolfreys A., Fedyk J., Bourner C., and Windebank S. The ability of the Comet assay to discriminate between genotoxins and cytotoxins. Mutagenesis 13 1 (1998) 89-94
34. Kirsch-Volders M., Sofuni T., Aardema M., Albertini S., Eastmond D., Fenech M., Ishidate Jr. M., Kirchner S., Lorge E., Morita T., Norppa H., Surralles J., Vanhauwaert A., and Wakata A. Report from the in vitro micronucleus assay working group. Mutat. Res. 540 2 (2003) 153-163
35. Kohn K.W. Assessment of DNA damage by filter elution assays. In: Simic M.G., Grossman L., and Upton A.C. (Eds). Mechanisms of DNA Damage and Repair (1986), Plenum Press, New York, London 101-118
36. Krokan H.E., Standal R., and Slupphaug G. DNA glycosylases in the base excision repair of DNA. Biochem. J. 325 (1997) 1-16
37. Kruman I.I., Kumaravel T.S., Lohani A., Pedersen W.A., Cutler R.G., Kruman Y., Haughey N., Lee J., Evans M., and Mattson M.P. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J. Neurosci. 22 (2002) 1752-1762
38. Kumaravel, T.S., Vilhar, B., Faux, S.P. Jha, A.N., in press. Comet assay measurements: a perspective. Cell Biol. Toxicol. [Electronic publication ahead of print].
39. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., and Wenger N.K. Treating to New Targets (TNT) investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352 (2005) 1425-1435
40. Mahley R.W., and Bersot T.P. Drug therapy for hypercholesterolemia and dyslipidemia. In: Hardman J.G., Limbird L.E., and Gilman A.G. (Eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. (2001), McGraw Hill, New York 971-1002
41. Mukhtar R.Y., Reid J., and Reckless J.P. Pitavastatin. Int. J. Clin. Pract. 59 (2005) 239-252
42. Naoumova R.P., O'Neill F.H., Dunn S., Neurwirth C.K., Taylor G.W., Axelson M., and Thompson G.R. Effect of inhibiting HMG-Coa reductase on 7α-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway. Eur. J. Clin. Invest. 29 (1999) 404-412
43. National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
44. Newman C.B., Palmer G., Silbershatz H., and Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am. J. Cardiol. 92 (2003) 670-676
45. Newman C., Tsai J., Szarek M., Luo D., and Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am. J. Cardiol. 97 1 (2006) 61-67
46. Noseda G., Darioli R., Keller U., Mordasini R., Shokry A., Schaffhauser B., and Riesen W. Evaluating the efficacy and tolerance of atorvastatin in hyperlipidemia in general practice (SWITCH Study). Schweiz. Med. Wochenschr. 130 (2000) 889-895
47. Olive P.L. DNA damage and repair in individual cells: aplications of the comet assay in radiobiology. Int. J. Radiat. Biol. 75 4 (1999) 395-405
48. Omar M.A., and Wilson J.P. FDA adverse event reports on statin-associated rhabdomyolysis. Ann. Pharmacother 36 (2002) 288-295
49. Pedersen T.R., and Tobert J.A. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Drug Safety 14 (1996) 11-24
50. Pedersen T.R., Faergeman O., Kastelein J.J., Olsson A.G., Tikkanen M.J., Holme I., Larsen M.L., Bendiksen F.S., Lindahl C., Szarek M., Tsai J., and Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
51. Peto R., Yusuf S., and Collins R. Cholesterol lowering trials in their epidemiological context. Circulation 72 (1985) 451
52. Phillips P.S., Haas R.H., Bannykh S., Hathaway S., Gray N.L., Kimura B.J., Vladutiu G.D., and England J.D. Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med. 137 (2002) 581-585
53. Pyorala K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., and Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20 (1997) 614-620
54. Raisuddin S., and Jha A.N. Relative sensitivity of fish and mammalian cells to sodium arsenate and arsenite as determined by alkaline single-cell gel electrophoresis and cytokinesis-block micronucleus assay. Environ. Mol. Mutagen. 44 1 (2004) 83-89
55. Raslova K., Dobiasova M., Nagyova A., Fabry R., Rauchova H., and Dusinska M. Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage. Eur. J. Clin. Pharmacol. 54 (1998) 697-699
56. Schrott H.G., Knapp H., Davila M., Shurzinske L., and Black D. Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study. Am. Heart J. 140 (2000) 249-252
57. Singh N.P. Apoptosis assessment by the DNA diffusion assay. Methods Mol. Med. 111 (2005) 55-67
58. Singh N.P., McCoy M.T., Tice R.R., and Schneider L.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 175 (1988) 184-191
59. Staffa J.A., Chang J., and Green L. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. 346 (2002) 539-540
60. Thomas P., Umegaki K., and Fenech M. Nucleoplasmic bridges are sensitive measure of chromosome rearrangement in the cytokinesis-block micronucleus assay. Mutagenesis 18 2 (2003) 187-194
61. Tice R.R., Agurell E., Anderson D., Burlinson B., Hartman A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.-C., and Sasaki Y.F. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 35 (2000) 206-221
62. Tolman K.G. The liver and lovastatin. Am. J. Cardiol. 89 (2002) 1374-1380
63. Umegaki K., and Fenech M. Cytokinesis-block micronucleus assay in WIL2-NS cells: a sensitive system to detect chromosomal damage induced by reactive oxygen species and activated human neutrophils. Mutagenesis 15 3 (2008) 261-269
64. Van der Harst P., Voors A.A., van Gilst W.H., Bohm M., and Van Veldhuisen D.J. Statins in the treatment of chronic heart failure: a systematic review. PLoS. Med. 3 8 (2006) e333
65. Van der Harst P., Voors A.A., van Gilst W.H., Bohm M., and Van Veldhuisen D.J. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc. Res. 71 (2006) 443-454
66. Van Goethem F., Lison D., and Kirsch-Volders M. Comparative evaluation of the in vitro micronucleus test and the alkaline single cell gel electrophoresis assay for the detection of DNA damaging agents: genotoxic effects of cobalt powder, tungsten carbide and cobalt-tungsten carbide. Mutat. Res. 392 1-2 (1997) 31-43
67. Wierzbicki A.S., Lumb P.J., Chik G., and Crook M.A. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with hypercholesterolemia. Int. J. Clin. Pract. 53 (1999) 609-611
68. Wojewódzka M., Kruszewski M., Iwanenko T., Collins A.R., and Szumiel I. Application of the comet assay for monitoring DNA damage in workers exposed to chronic low-dose irradiation. I. Strand breakage. Mutat. Res. 416 (1998) 21-35